Overview

A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on pancreatic cancer in patients who have an inherited, deleterious BRCA1 or BRCA2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed for vitamin C

Phase:

Phase 1

Details

Lead Sponsor:

General Oncology, Inc.

Treatments:

Ascorbic Acid
Carmustine
Ethanol
Hydroxocobalamin
Melphalan
Vitamin B 12
Vitamin B Complex
Vitamins